Extramedullary blast crisis in a patient with chronic myelogenous leukemia in complete cytogenetic and molecular remission on interferon-α therapy

Leukemia Research

Volumn 24, Issue 8, 2000, Pages 733-735

  Beedassy, Ashok ^a   Topolsky, David ^a   Styler, Michael ^a   Crilley, Pamela ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Chronic myelogenous leukemia; Extramedullary blast crisis; Interferon

Indexed keywords

ALPHA INTERFERON; ASPARAGINASE; BCR ABL PROTEIN; BUSULFAN; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADULT; ARTICLE; BLAST CELL CRISIS; BONE MARROW; BONE MARROW TRANSPLANTATION; CASE REPORT; CEREBROSPINAL FLUID; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TESTIS BIOPSY; TESTIS TUMOR;

ADULT; ANTINEOPLASTIC AGENTS; BLAST CRISIS; FUSION PROTEINS, BCR-ABL; GENES, ABL; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; MALE; REMISSION INDUCTION;

EID: 0033916380     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(00)00039-4     Document Type: Article

References (14)

1. Specchia G., Palumbo G., Pastore D., Mininni D., Mestice A., Liso V. Extramedullary blast crisis in chronic myeloid leukemia. Leuk. Res. 20:1996;905.
2. Jacknow G., Frizzera G., Gajl-Peczalska K., Banks P., Arthur D.C., McGlave P.B. et al. Extramedullary presentation of the blast crisis of chronic myelogenous leukemia. Br. J. Haematol. 65:1985;225.
3. Talpaz M., McCredie K.B., Mavligit G.M., Gutterman J.U. Leucocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood. 62:1983;689.
4. The Italian Cooperative Study Group on Chronic myeloid Leukemia Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New Engl. J. Med. 1994;330:820.
5. O'Brien S., Witt R., Talpaz M., Kantarjian H. Extramedullary blast crisis in a patient with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic remission. Cancer. 67:1991;1946-1949.
6. Kantarjian H.M., Smith T.L., O'Brien S., Beran M., Pierce S., Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann. Intern. Med. 122:1995;254.
7. Hochhaus A., Lin F., Reiter R., Skladny H., van Rhee F., Shepherd P.C.A. et al. Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-α Br. J. Haematol. 91:1995;126.
8. Kurzrock R., Estrov Z., Kantarjian K., Talpaz M. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain negativity. J. Clin. Oncol. 16:1998;1526.
9. Hochhaus A., Lin F., Reiter R., Skladny H., Mason P.J., van Rhee F. et al. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-α therapy by competitive polymerase chain reaction. Blood. 87:1996;1549.
10. Einhorn S., Grander D. Why do so many patients fail to respond to interferon therapy? J. Interferon Cytokine Res. 16:1996;275.
11. Freund M., von Wusow P., Diedrich H., Eisert R., Link H., Wilke H. et al. Recombinant human interferon (IFN) alpha2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br. J. Haematol. 72:1989;350.
12. Smith R.A., Norris F., Palmer D., Bernhardt L., Wills R.J. Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration. Clin. Pharmacol. Ther. 37:1985;85.
13. Derderian P.M., Kantarjian H.M., Talpaz M., O'Brien S., Cork A., Estey E. et al. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am. J. Med. 94:1993;69.
14. Faderl S., Talpaz M., Kantarjian H., Estrov Z. Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Blood. 93:1999;2755.